Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006–2014

Abstract Background In Italy, the incidence of Invasive Meningococcal Disease (IMD) was around 0.28 per 100,000 over the last years. Since the risk IMD is usually high among infants aged less than 1 year, we decided to evaluate the trend of IMD cases reported between 2006 and 2014 in this age group....

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2015-07, Vol.33 (31), p.3678-3681
Main Authors: Stefanelli, P, Fazio, C, Neri, A, Boros, S, Renna, G, Pompa, M.G
Format: Article
Language:English
Subjects:
Allergy and Immunology
Bacterial diseases
Epidemiological Monitoring
Epidemiology
Female
Humans
IMD
Immunization
Incidence
Infant
Infant, Newborn
Infants
Italy - epidemiology
Male
Meningitis
Meningitis, Meningococcal - epidemiology
Meningitis, Meningococcal - microbiology
Meningitis, Meningococcal - prevention & control
Meningococcal Vaccines - administration & dosage
Meningococcal Vaccines - immunology
Multiplex Polymerase Chain Reaction
Neisseria meningitidis
Neisseria meningitidis - immunology
Neisseria meningitidis - isolation & purification
Serotyping
Surveillance
Vaccine
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background In Italy, the incidence of Invasive Meningococcal Disease (IMD) was around 0.28 per 100,000 over the last years. Since the risk IMD is usually high among infants aged less than 1 year, we decided to evaluate the trend of IMD cases reported between 2006 and 2014 in this age group. In particular, the study aim was to describe the main characteristics of IMD cases in infants following the introduction of MCC vaccine (2005) and to estimate the number of cases which are potentially preventable through early vaccination. Methods The National Surveillance System of Bacterial Meningitis was established in 1994 and in 2007 was extended to all invasive bacterial diseases. Clinical data and isolates and/or clinical samples are collected from hospitalized patients throughout the country. IMD cases are reported by clinicians to the local health authorities, and samples are sent to the Reference Laboratory at the Istituto Superiore di Sanità for further characterization and storage at −80 °C. In particular, serogroup identification is obtained by agglutination with commercial antisera or by multiplex PCR. Results The annual incidence for infants
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2015.06.032